Efficacy and safety of fluticasone furoate 100µg once-daily in patients with persistent asthma: a 24- week placebo and active-controlled randomised trial Jan Lötvall, Eugene R Bleecker, William W Busse, Paul M O’Byrne, Ashley Woodcock, Edward M Kerwin, Sally Stone, Richard Forth, Loretta Jacques, Eric D Bateman ONLINE SUPPLEMENTARY MATERIAL Additional methods Study exclusion criteria Exclusion criteria included a history of life-threatening asthma, clinically significant and unresolved respiratory infection <4 weeks prior to screening, asthma exacerbation requiring steroid treatment or resulting in hospitalisation within 6 months of screening, or other clinically significant disease states. Randomisation exclusion criteria To be eligible for randomisation patients were required to exhibit evening pre-dose forced expiratory volume in 1s (FEV 1 ) of 40–90% predicted; the continued presence of symptoms (combined daily asthma symptom score ≥1 or salbutamol use on four of the last 7 days of run-in); and compliance with run-in inhaled corticosteroids and diary card entry (4 of the last 7 days of screening). Patients not
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Efficacy and safety of fluticasone furoate 100µg once-daily in
patients with persistent asthma: a 24-week placebo and active-
controlled randomised trial
Jan Lötvall, Eugene R Bleecker, William W Busse, Paul M O’Byrne,
Ashley Woodcock, Edward M Kerwin, Sally Stone, Richard Forth, Loretta Jacques,
Eric D Bateman
ONLINE SUPPLEMENTARY MATERIAL
Additional methods
Study exclusion criteria
Exclusion criteria included a history of life-threatening asthma, clinically significant and